This systematic review and network meta-analysis evaluated the efficacy and cost-effectiveness of first-line immune checkpoint inhibitors combined with targeted therapy for advanced renal cell carcinoma in the Chinese healthcare context. Researchers analyzed seven Phase III randomized controlled trials encompassing 4,973 patients, comparing ICI-targeted combinations against sunitinib using network meta-analysis to assess progression-free survival and overall survival outcomes. A partitioned survival model was subsequently developed to conduct cost-effectiveness analysis over a 20-year horizon. Results demonstrated that pembrolizumab plus lenvatinib ranked highest for progression-free survival, while toripalimab plus axitinib achieved superior overall survival outcomes and the lowest incremental cost-effectiveness ratio at $62,204.37 per quality-adjusted life-year. However, all evaluated regimens exceeded the willingness-to-pay threshold of $40,332.35 per quality-adjusted life-year established for the Chinese healthcare system. These findings provide critical insights for healthcare policy makers and clinicians regarding the clinical benefits and economic implications of combining immune checkpoint inhibitors with targeted therapies in treating advanced renal cell carcinoma.

Pancreatic ductal adenocarcinoma (PDAC) remains one of oncology's most lethal cancers, with only 13.7% five-year survival rates and even grimmer outcomes in previously treated metastatic settings, where median overall survival is five to seven months. Despite KRAS mutations driving over 90% of pancreatic cancers for decades, the protein remained undruggable until recently due to its lack of well-defined pockets amenable to small-molecule inhibitors. While sotorasib and adagrasib, approved in 2021 and 2022 respectively, represented landmark breakthroughs by targeting the G12C mutation, this variant accounts for only 1-2% of PDAC cases. More prevalent mutations include G12D (40%), G12V (30%), and G12R (20%), necessitating alternative approaches. Daraxonrasib, a pan-RAS inhibitor, addresses this gap by targeting mutant and wild-type KRAS, HRAS, and NRAS isoforms in their active state. The drug forms a complex with cyclophilin A upon cellular entry, enabling high affinity binding to active RAS and overcoming previously insurmountable barriers. This innovation could transform treatment for the majority of PDAC patients currently lacking targeted options.

Allogeneic CAR-T cell therapy represents a significant advancement in treating T-cell malignancies, offering substantial scalability advantages over autologous approaches. Unlike autologous CAR-T therapies that require patient-specific cell engineering, allogeneic CAR-T utilizes donor-derived cells that can be manufactured at scale from a single source, dramatically reducing production time and costs while increasing accessibility. The primary challenge involves managing graft-versus-host disease (GVHD), a potentially severe complication arising when donor immune cells attack recipient tissues. Recent developments have focused on engineering strategies to mitigate GVHD risk while preserving the therapeutic anti-tumor effects. By implementing off-the-shelf manufacturing protocols and refined cell engineering techniques, developers can produce consistent, high-quality allogeneic CAR-T products suitable for broader patient populations. This scalability potential positions allogeneic CAR-T as a transformative approach in oncology, particularly for treating T-cell malignancies where rapid, standardized treatment deployment is critical. The technology's commercial viability depends on successfully balancing safety profiles with manufacturing efficiency.

The Cell and Gene Therapy (CGT) Access Model represents a groundbreaking federal initiative designed to expand access to innovative treatments for rare and severe diseases through outcomes-based agreements (OBAs) negotiated by the Centers for Medicare & Medicaid Services on behalf of state Medicaid agencies. This multi-year, voluntary model marks the first time the federal government has engaged in such negotiations with CGT manufacturers. The initial focus targets gene therapy treatments for sickle cell disease, a genetic blood disorder affecting Medicaid beneficiaries. States and manufacturers entered the program through a Request for Application process, with participation beginning between January 2025 and January 2026. The model aims to increase patient access to potentially transformative treatments while improving health outcomes and reducing costs to state Medicaid programs. Recognizing that gene therapy for sickle cell disease requires extended inpatient hospital stays and myeloablative chemotherapy that causes infertility, the model mandates participating manufacturers cover fertility preservation services. This comprehensive approach addresses both treatment access and critical patient support needs, with potential expansion to additional disease conditions in the future.

Chimeric antigen receptor (CAR) T-cell therapy has traditionally been accessible only through tertiary academic centers, creating significant barriers for patients in community settings. At the Community Oncology Alliance Payer Exchange & Innovation Summit, payer, provider, and network leaders convened to address this gap and establish pathways for expanding CAR T access to community oncology practices. The panel, moderated by Kiana Mehring from Florida Cancer Specialists & Research Institute, featured Anthony Bonagura from Optum, Aaron Lyss from OneOncology, and Ameet Patel from FCSRI. Participants identified three key success metrics: clinical outcomes matching those at academic centers, faster and improved patient access, and manageable financial burden for community practices. A critical innovation discussed was "brain-to-vein" time—the period from initial diagnosis to cellular therapy administration—where delays cause approximately 20 to 25 percent of patients to become ineligible. Panelists emphasized that success requires balancing diverse stakeholder expectations, including patient preferences, employer cost concerns, and the unrecognized work of care navigators and coordinators. This collaborative effort signals industry recognition that decentralizing CAR T access is essential for equitable patient care delivery.

Clinical trials have always been known to be executed in medical facilities. When the Covid-19 pandemic struck in 2020, much devastation occurred. The pandemic put a pause on many operations, including clinical trials. Clinical researchers needed to find a way to continue. This was done so by implementing a new upcoming way of research, decentralized clinical trials; Decentralized clinical trials are also referred to as DCT’s. The purpose of a DCT is to remove in-person contact between the study team and the patients/subjects.

BioNTech and Genentech have terminated the Phase 2 BNT122-01 trial of autogene cevumeran, a personalized mRNA cancer vaccine, after an independent monitoring board identified a survival imbalance between treatment groups. The trial enrolled approximately 327 patients with Stage II high-risk or Stage III colorectal cancer who had undergone surgery but retained circulating tumor DNA, indicating residual microscopic disease. The vaccine was administered as monotherapy without checkpoint inhibitor combination, compared against watchful waiting, the current standard of care. While the monitoring board detected more deaths in the vaccine arm and found no new safety signals, this represents a meaningful negative result given the trial's rigorous design testing whether individualized mRNA immunotherapy could work as standalone adjuvant treatment. Colorectal cancer presents a particularly challenging target, characterized as a cold tumor with an immunosuppressive microenvironment and historically poor immunotherapy responsiveness. The trial had already crossed its futility boundary in October 2025 before this termination decision, suggesting limited benefit prospects were evident prior to the survival imbalance identification.

Decentralized clinical trials (DCTs) offer promising solutions to barriers that prevent cancer patients from participating in research, particularly those in rural and medically underserved communities. The ACCC's Advancing Decentralized Clinical Trials in the Community Setting Roundtable Series explored how remote consent, telehealth, local laboratory and imaging services, digital health technologies, and mobile health professionals can improve access. However, successful implementation requires more than technology adoption—it demands practical workflows, clear oversight structures, engaged sponsors, prepared staff, and organizational cultures supporting innovation. A critical insight emerged: distance equals disparity. Geographic distance creates substantial obstacles to both routine oncology care and trial participation, with surveys showing approximately 89-90% of rural respondents unaware of clinical trials. The roundtable emphasized that meaningful access requires comprehensive community engagement strategies, including outreach, community advisory boards, culturally responsive recruitment materials, and patient representation in trial-review processes. These foundational efforts to build awareness and trust must occur well before patients need treatment options, recognizing that patients should never encounter clinical trials for the first time during urgent care situations. Sustainable decentralization demands equity-focused planning and community-centered approaches.

Personalized cancer vaccines represent a promising evolution in immunotherapy, moving beyond earlier approaches that targeted shared tumor-associated antigens with limited clinical success. These new vaccines sequence individual tumors to identify mutation-derived neoantigens—unique cancer-specific targets invisible to immune tolerance mechanisms—and create patient-specific formulations. Recent clinical progress demonstrates neoantigen-specific immune responses across melanoma, pancreatic cancer, and renal cell carcinoma. A significant breakthrough occurred in August 2026 when the phase III INTerpath-001 trial showed intismeran autogene combined with pembrolizumab met its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival in resected high-risk melanoma patients. The fundamental advantage of this approach lies in exploiting somatic mutations that alter amino acid sequences, creating truly foreign targets that escape the immune tolerance mechanisms that eliminated reactivity against self-antigens during normal T-cell development. As emphasized in a 2026 Nature Communications review by Nune Markosyan and Robert Vonderheide, this distinction between self-antigens and neoantigens addresses a critical immunological limitation of previous cancer vaccines. The field now faces the critical question of whether precisely targeted neoantigen immunity can translate into durable clinical benefits across diverse cancer types.

Pancreatic ductal adenocarcinoma (PDAC) has proven resistant to immunotherapies that succeeded against other cancers. New research published in Cell reveals a promising combination strategy: pairing KRAS inhibitors with 21h10, a synthetic mimic of the immune cytokine IL-21. In mouse models, this combination produced durable tumor remissions by activating CD4 T cells—contrary to conventional approaches focusing on CD8 T cells—which recruited macrophages to eliminate tumors. The KRAS inhibitor creates a therapeutic window by shrinking tumors and reducing immunosuppressive signals, allowing 21h10 to drive potent anti-tumor responses. Remarkably, complete tumor clearance occurred without requiring CD8 T cells or MHC class I expression on tumor cells. Instead, 21h10 expanded Th1-polarized CD4 T cells that produced interferon-gamma. Critically, T cells from human pancreatic tumors demonstrated responsiveness to 21h10 in laboratory experiments, suggesting this mechanism may translate to patients. This research challenges existing immunotherapy paradigms and offers a novel approach to extend KRAS inhibitor benefits in pancreatic cancer, a historically difficult-to-treat malignancy.

AstraZeneca's ETCAMAH (camizestrant) has received FDA accelerated approval in combination with CDK4/6 inhibitors (abemaciclib, palbociclib, or ribociclib) for treating hormone receptor-positive, HER2-negative advanced or metastatic breast cancer with emergent ESR1 mutations detected during aromatase inhibitor and CDK4/6 inhibitor therapy. The approval follows results from the pivotal SERENA-6 Phase III trial, presented at the 2025 American Society of Clinical Oncology Annual Meeting and published in The New England Journal of Medicine. The trial demonstrated that the combination reduced disease progression or death risk by 56 percent compared to standard aromatase inhibitor therapy with CDK4/6 inhibitors, with a hazard ratio of 0.44 and median progression-free survival of 16.0 versus 9.2 months. This approval represents AstraZeneca's tenth FDA authorization this year and fourth in breast cancer, marking the first first-line medicine of its type utilizing circulating tumor DNA detection. The combination addresses approximately one-third of advanced breast cancer patients developing ESR1 mutations, enabling earlier therapeutic intervention before clinical progression and potentially improving patient outcomes and quality of life.

In vivo CAR-T cell therapy represents a transformative approach in oncology and autoimmune disease treatment, directly engineering T cells within patients' bodies rather than ex vivo. This method leverages advanced delivery technologies including lipid nanoparticles and lentiviral vectors to reduce manufacturing costs, accelerate timelines, and enhance therapeutic accessibility. However, the complexity of integrating targeted delivery, gene expression, immune response, and safety assessment demands rigorous preclinical validation. WuXi Biology has developed a comprehensive integrated framework addressing these challenges, establishing a standardized workflow from molecular design through in vivo validation. The framework encompasses three synergistic core modules: the first utilizes mature antibody discovery platforms—phage display, hybridoma technology, and single B-cell analysis—to identify and characterize high-affinity, high-specificity binders and CAR extracellular antigen-binding domains. Additionally, high-throughput CAR functional screening systems, including Jurkat reporter assays, evaluate CAR-mediated functionality. This end-to-end continuity enhances preclinical research efficiency and data interpretability, effectively supporting progression toward Investigational New Drug applications and advancing in vivo CAR-T product development.

Antimicrobial resistance (AMR) represents an escalating threat to modern medicine, as bacteria evolve to resist existing antibiotics, compromising everything from routine surgeries to cancer treatment and organ transplantation. The World Health Organization identifies AMR as a critical global health crisis, with resistant infections linked to approximately 4.95 million deaths worldwide in 2019, including 1.27 million deaths directly attributable to resistance. Unchecked AMR could reduce global GDP by 3.8 percent by 2050 and push 28 million people into poverty according to World Bank projections. In response, stakeholders across healthcare, biotechnology, regulation, and investment sectors are increasingly exploring alternative treatment strategies. Phage therapy, which uses naturally occurring viruses called bacteriophages to target harmful bacteria, has emerged as a promising area attracting renewed scientific and commercial attention. This approach sits at the intersection of healthcare innovation, biotechnology investment, regulatory strategy, and life sciences risk management, offering potential solutions to combat difficult-to-treat infections as conventional antibiotics lose efficacy.

Lipids are fundamental components of the brain, crucial for synaptic transmission and signal propagation. Altered brain lipid composition is associated with common and rare neuropathologies, yet the spatial organization of the mammalian brain lipidome remains insufficiently characterized compared with other modalities. Here we mapped the membrane-lipid architecture of the adult mouse brain at micrometric scale, across sexes and during pregnancy. This lipid brain atlas reveals that lipids describe a fine-grained biochemical structure that aligns with functional anatomy. Membrane-lipid spatial heterogeneity clusters into territories, which we termed ‘lipizones’. Lipizones partially mirror cell-type territories, but also capture distal axon terminals.

This review examines the latest advances in in vivo CAR-T cell therapy, a promising immunological approach for treating cancer and other diseases. Rather than engineering T cells outside the body, in vivo CAR-T therapy generates chimeric antigen receptor-expressing cells directly within patients, potentially improving treatment accessibility and reducing manufacturing complexity. The article surveys recent progress in this field, detailing emerging techniques and methodologies that enhance CAR-T cell generation and function in living organisms. Key developments include innovations in genetic engineering approaches, optimized delivery mechanisms, and strategies to overcome immunological barriers. The review highlights clinical and preclinical findings demonstrating improved efficacy and safety profiles compared to traditional ex vivo approaches. In vivo CAR-T therapy matters significantly because it addresses critical limitations of conventional CAR-T treatments, including high costs, extended production timelines, and manufacturing standardization challenges. By enabling direct cellular reprogramming within patients, this approach could democratize access to advanced cancer immunotherapies and expand treatment possibilities for diverse patient populations and disease indications.

# Professional Summary This article published in the Cureus Journal of Medical Science addresses innovative therapeutic approaches beyond traditional antibiotic treatments. The research, authored by Benny Vijayanandh Avanigadda, Raja Krishna Venigalla, Renusri Ede, Pranathi Reddy Jetti, Venkataramana Kandi, and Tarun Kumar Suvvari, explores alternative strategies to combat antimicrobial resistance and infectious diseases. The article likely examines emerging technologies and methodologies such as bacteriophage therapy, antimicrobial peptides, immunotherapy, or targeted drug delivery systems that offer potential solutions to antibiotic-resistant pathogens. Given the escalating global health threat posed by antimicrobial resistance, this comprehensive review is significant for medical professionals, pharmaceutical researchers, and healthcare policymakers seeking evidence-based alternatives to conventional antibiotics. The findings contribute to the growing body of literature supporting the development and clinical implementation of next-generation therapeutic options that can complement or replace traditional antibiotic regimens in various clinical scenarios.

Amgen announced landmark results from the Phase 3 DeLLphi-305 study demonstrating that IMDELLTRA (tarlatamab-dlle), a bispecific T-cell engager therapy, in combination with AstraZeneca's Imfinzi (durvalumab) significantly improved overall survival compared to durvalumab alone in patients with extensive stage small cell lung cancer. The study evaluated IMDELLTRA as first-line maintenance treatment for ES-SCLC patients whose disease had not progressed following initial treatment with durvalumab, platinum-based chemotherapy, and etoposide. Beyond the primary endpoint, the combination also achieved statistically significant improvements in progression-free survival and objective response rate. The safety profile remained consistent with known profiles of individual medicines, with no new safety signals identified. This represents the first Phase 3 study of a BiTE therapy to demonstrate overall survival benefit in the first-line maintenance setting for ES-SCLC. Given that extensive stage small cell lung cancer remains one of the most aggressive cancers with rare substantial survival improvements, these results potentially shift the treatment paradigm and establish a new standard of care earlier in the disease journey for affected patients.

Breast cancer represents the most common malignancy among women worldwide, with hormone receptor-positive, HER2-low disease presenting particular clinical challenges once resistance develops to standard endocrine therapy and CDK4/6 inhibitors. This case report from Shenzhen Hospital, Southern Medical University, documents a 45-year-old female patient with HR+/HER2-low metastatic breast cancer who had progressed on conventional treatments. The patient received a combination of trastuzumab deruxtecan, a HER2-directed antibody-drug conjugate, paired with fulvestrant, a selective estrogen receptor degrader. The treatment demonstrated significant clinical efficacy and favorable tolerability, achieving a progression-free survival of 26 months without any grade 3 or higher adverse events. HER2-low breast cancer, defined as HER2 1+ or 2+ expression with negative in situ hybridization results, represents approximately 60% of HER2-negative cases and has emerged as an important therapeutic target. The authors suggest this combination approach may constitute a promising strategy for patients with advanced, treatment-refractory HR+/HER2-low breast cancer, potentially offering clinicians a valuable option for managing this previously difficult-to-treat patient population.

# Summary This Nature article, authored by Boston Consulting Group healthcare experts, examines the evolving landscape of in vivo CAR T cell therapies. In vivo CAR T approaches represent a significant advancement in cancer immunotherapy, enabling T cells to be engineered within the patient's body rather than through traditional ex vivo manufacturing. The analysis, supported by contributions from H. Zhang and Z. Chowdhury, provides insights into both preclinical and clinical developments in this therapeutic domain. The piece is particularly valuable for biopharmaceutical stakeholders seeking to understand how in vivo CAR T strategies are reshaping treatment paradigms. By contrasting in vivo approaches with conventional ex vivo CAR T manufacturing, the article highlights potential advantages including reduced manufacturing complexity, lower costs, and improved accessibility. This comprehensive review matters because in vivo CAR T therapies could democratize advanced cellular immunotherapy, extending effective cancer treatments to broader patient populations while addressing supply chain limitations that currently constrain ex vivo CAR T deployment.

Traditional screening-based drug discovery is inherently limited by the astronomical scale of the chemical space. Generative modelling offers a compelling alternative to the classical search paradigm and enables rational, bottom-up design of novel and target-specific small molecules. However, its impact has been hampered by challenges in synthetic accessibility of the designed compounds and lack of large-scale experimental validation. Here, we introduce LDDM (Large Drug Discovery Model), a generative framework that supports a range of drug discovery tasks, including constrained and unconstrained docking, fragment linking and growing, and de novo design. We further introduce a programmable design algorithm that enables accurate design of synthetically accessible compounds satisfying various fine-grained objectives.